MARKET TALK: Jefferies Upgrades Genmab To Buy
20th Jul 2010 08:14
0714 GMT [Dow Jones] Jefferies upgrades Genmab (GEN.KO) to buy from hold, and lifts its target price to DKK100 from DKK75, as the removal of the funding overhang and multiple potential catalysts should drive the stock from currently depressed levels and improve broadly negative investor sentiment. N
Read moreEARNINGS PREVIEW: Glaxo 2Q Pre-Restructuring Net Pft Seen -11%
19th Jul 2010 16:05
GlaxoSmithKline (GSK): 2Q Earnings Due: April 21 at 1100 GMT DJ Survey of 13 Analysts Average 2Q 2010 Net Profit Before Major Restructuring: GBP1.40B, -11% (GBP1.57B in 2Q 2009) Average 2Q Revenue: GBP6.98B, +3.4% (GBP6.75B) Note: Glaxo last week said it will record a charge of GBP1.57 billion i
Read moreTIP SHEET: Federated Dividend Fund Plows Through Market Swings
19th Jul 2010 12:36
(This article was originally published Friday.) By Brian Baskin Of DOW JONES NEWSWIRES The Federated Strategic Value Dividend Fund (SVAAX) is happy to leave stock picking to the so-called experts. The fund invests in companies that distribute large, regular dividends, and aims to
Read moreEARNINGS FORECAST TABLE: GlaxoSmithKline 2Q 2010
19th Jul 2010 11:27
FRANKFURT (Dow Jones)--The following is a summary of analysts' forecasts for GlaxoSmithKline PLC's (GSK) second-quarter results, based on a poll of 13 analysts by Dow Jones Newswires (in million GBP, EPS, dividend and target price in pence, according to IFRS). Earnings figures are scheduled to be re
Read moreMARKET TALK: Watch Out For Stolen Glaxo Asthma Inhalers
16th Jul 2010 20:21
3:21 (Dow Jones) Advair Diskus asthma inhalers that were stolen from a GlaxoSmithKline (GSK) warehouse in Virginia last year have been found in some pharmacies, US FDA says Friday. Agency says safety and effectiveness of stolen products can't be assured, and they shouldn't be used. People who have A
Read moreTIP SHEET: Federated Dividend Fund Plows Through Market Swings
16th Jul 2010 20:00
By Brian Baskin Of DOW JONES NEWSWIRES The Federated Strategic Value Dividend Fund (SVAAX) is happy to leave stock picking to the so-called experts. The fund invests in companies that distribute large, regular dividends, and aims to have returns pegged to those payments rather than shor
Read moreFDA Panel Vote Against Vivus Brings More Obesity Drug Questions
16th Jul 2010 18:38
By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--A Food and Drug Administration panel review of Vivus Inc.'s (VVUS) experimental weight-loss drug Qnexa was expected to bring clarity to the approvability of the latest crop of obesity drugs, but instead it only has raised more ques
Read morePRESS RELEASE: FDA Warns Consumers, Pharmacists, and Wholesalers Not to Use Stolen Advair Diskus Inhalers
16th Jul 2010 18:35
FDA NEWS RELEASE For Immediate Release: July 16, 2010 Media Inquiries: Elaine Gansz Bobo, 301-796-7567 Consumer Inquiries: 888-INFO-FDA FDA Warns Consumers, Pharmacists, and Wholesalers Not to Use Stolen Advair Diskus Inhalers The FDA is warning the public that certain Advair Dis
Read moreWeek ahead: GlaxoSmithKline, Capita, Ryanair
16th Jul 2010 13:05
In GlaxoSmithKline's second quarter results on Wednesday, Charles Stanley is looking for revenues of £6.99bn and a pre-tax profit of £2m. 'Expect these results to show continued growth in emerging market activities and a continued positive contribution over the quarter from H1N1 pandemic 'flu prepa
Read moreHEARD ON THE STREET: Glaxo's Celebrations To Be Short-Lived
16th Jul 2010 07:30
This story was originally published on Thursday. By Hester Plumridge A DOW JONES COLUMN It's a victory certainly, but it feels a little hollow. GlaxoSmithKline is close to settling a three-year dispute over the future of its diabetes drug Avandia, one of the U.K. drugs giant's top-five be
Read more3rd UPDATE: FDA Panel Rejects Vivus Weight-Loss Drug Qnexa
15th Jul 2010 23:20
(Updates with Vivus comment in sixth paragraph.) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A U.S. federal advisory panel Thursday rejected Vivus Inc.'s (VVUS) experimental weight-loss drug Qnexa on concerns that potential safety issues could be magnified if
Read more2nd UPDATE: FDA Panel Rejects Vivus Weight-Loss Drug Qnexa
15th Jul 2010 22:29
(Updates with FDA comments and other details) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A federal advisory panel Thursday rejected Vivus Inc.'s (VVUS) experimental weight-loss drug Qnexa on concerns potential safety concerns could be magnified if used by m
Read moreADR Report: Shares Close Mixed After Late Bank, BP Rally
15th Jul 2010 22:26
By Emily Glazer Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--International companies trading in New York had a mixed close Thursday as stocks pared losses while financials recovered ground. Financial stocks, which are particularly susceptible to economic headwinds, fell for much of the s
Read moreHEARD ON THE STREET: Glaxo's Celebrations To Be Short-Lived
15th Jul 2010 16:34
By Hester Plumridge A DOW JONES COLUMN It's a victory certainly, but it feels a little hollow. GlaxoSmithKline is close to settling a three-year dispute over the future of its diabetes drug Avandia, one of the U.K. drugs giant's top-five best-sellers. That should remove one uncertainty hangi
Read moreFTSE 100 movers: Miners and financials head lower
15th Jul 2010 16:17
Footsie is heading lower as miners and financials fall back. Metals prices are recovering but ENRC, Rio Tinto, Xstrata and Kazakhmys are all lower. Barclays leads the fallers. There is also profit taking in ARM after yesterday's rise. Global information services company Experian is higher af
Read more